Total trials
375
Active
50
Phase 3
23
Total enrollment
990,189
Pipeline matrix
Showing 6 of 6 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Lavender essential oil 10%, diluted in 90% olive oil | — | — | — | — | — | 1 | |
| Apixaban 2.5 MG Oral Tablet [ELIQUIS] | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | — | 1 | |
| MVX-ONCO-2 | — | — | — | — | — | 1 | |
| Lysergic Acid Diethylamide (LSD) or psilocybin | — | — | — | — | — | 1 | |
| Ryeqo treatment | — | — | — | — | — | 1 |
Next readouts
- 2022-06
- 2025-04-30
- 2026-03-31
- 2026-08-31
- 2026-11
- 2026-12-30
Top conditions
- Pain6
- Venous Thromboembolism5
- Emergencies5
- Obesity5
- Stroke5
- Healthy5
- Coronary Artery Disease5
- Critical Illness5
Frequently asked questions about University Hospital, Geneva
- How many clinical trials does University Hospital, Geneva have on ClinicalTrials.gov?
- University Hospital, Geneva is listed as the lead sponsor on 375 clinical trials in ClinicalTrials.gov, 50 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University Hospital, Geneva's trials are in Phase 3?
- 23 of University Hospital, Geneva's trials are in Phase 3, spread across 6 active drug programs.
- What therapeutic areas does University Hospital, Geneva focus on?
- University Hospital, Geneva's most-studied conditions on ClinicalTrials.gov are Pain, Venous Thromboembolism, Emergencies, Obesity, Stroke.
- When are University Hospital, Geneva's next clinical trial readouts?
- University Hospital, Geneva has 6 upcoming primary-completion readouts tracked here; the soonest is “Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer”, expected around 2022-06.